159 related articles for article (PubMed ID: 31867329)
1. Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms.
Huang S; Chen Y; Liang ZM; Li NN; Liu Y; Zhu Y; Liao D; Zhou XZ; Lu KP; Yao Y; Luo ML
Front Cell Dev Biol; 2019; 7():322. PubMed ID: 31867329
[TBL] [Abstract][Full Text] [Related]
2. Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.
Rajbhandari P; Finn G; Solodin NM; Singarapu KK; Sahu SC; Markley JL; Kadunc KJ; Ellison-Zelski SJ; Kariagina A; Haslam SZ; Lu KP; Alarid ET
Mol Cell Biol; 2012 Jan; 32(2):445-57. PubMed ID: 22064478
[TBL] [Abstract][Full Text] [Related]
3. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
[TBL] [Abstract][Full Text] [Related]
4. Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways.
Liao XH; Zhang AL; Zheng M; Li MQ; Chen CP; Xu H; Chu QS; Yang D; Lu W; Tsai TF; Liu H; Zhou XZ; Lu KP
Sci Rep; 2017 Mar; 7():43639. PubMed ID: 28262728
[TBL] [Abstract][Full Text] [Related]
5. The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer.
Namgoong GM; Khanal P; Cho HG; Lim SC; Oh YK; Kang BS; Shim JH; Yoo JC; Choi HS
J Biol Chem; 2010 Jul; 285(31):23829-41. PubMed ID: 20479004
[TBL] [Abstract][Full Text] [Related]
6. Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation.
Rajbhandari P; Schalper KA; Solodin NM; Ellison-Zelski SJ; Ping Lu K; Rimm DL; Alarid ET
Oncogene; 2014 Mar; 33(11):1438-47. PubMed ID: 23542176
[TBL] [Abstract][Full Text] [Related]
7. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
8. Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.
Lian X; Lin YM; Kozono S; Herbert MK; Li X; Yuan X; Guo J; Guo Y; Tang M; Lin J; Huang Y; Wang B; Qiu C; Tsai CY; Xie J; Gao ZJ; Wu Y; Liu H; Zhou XZ; Lu KP; Chen Y
J Hematol Oncol; 2018 May; 11(1):73. PubMed ID: 29848341
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer.
Xu R; Yang X; Tang B; Mao Y; Jiang F
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38714534
[TBL] [Abstract][Full Text] [Related]
10. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
Wu W; Xue X; Chen Y; Zheng N; Wang J
Pharmacol Res; 2022 Oct; 184():106456. PubMed ID: 36116709
[TBL] [Abstract][Full Text] [Related]
11. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.
Yang D; Luo W; Wang J; Zheng M; Liao XH; Zhang N; Lu W; Wang L; Chen AZ; Wu WG; Liu H; Wang SB; Zhou XZ; Lu KP
J Control Release; 2018 Jan; 269():405-422. PubMed ID: 29170140
[TBL] [Abstract][Full Text] [Related]
12. Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/β-catenin oncogenic pathways.
Zhang Z; Yu W; Zheng M; Liao X; Wang J; Yang D; Lu W; Wang L; Zhang S; Liu H; Zhou XZ; Lu KP
Mol Carcinog; 2019 Aug; 58(8):1450-1464. PubMed ID: 31026381
[TBL] [Abstract][Full Text] [Related]
13. Prolyl isomerase PIN1 negatively regulates SGK1 stability to mediate tamoxifen resistance in breast cancer cells.
Jo A; Yun HJ; Kim JY; Lim SC; Choi HJ; Kang BS; Choi BY; Choi HS
Anticancer Res; 2015 Feb; 35(2):785-94. PubMed ID: 25667458
[TBL] [Abstract][Full Text] [Related]
14. All-
Kim G; Bhattarai PY; Oh CH; Choi HS
Anticancer Res; 2019 Dec; 39(12):6537-6546. PubMed ID: 31810919
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
[TBL] [Abstract][Full Text] [Related]
16. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
Toma S; Raffo P; Nicolo G; Canavese G; Margallo E; Vecchio C; Dastoli G; Iacona I; Regazzi-Bonora M
Int J Oncol; 2000 Nov; 17(5):991-1000. PubMed ID: 11029503
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells.
Lu M; Mira-y-Lopez R; Nakajo S; Nakaya K; Jing Y
Oncogene; 2005 Jun; 24(27):4362-9. PubMed ID: 15870697
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha.
Gianni' M; Boldetti A; Guarnaccia V; Rambaldi A; Parrella E; Raska I; Rochette-Egly C; Del Sal G; Rustighi A; Terao M; Garattini E
Cancer Res; 2009 Feb; 69(3):1016-26. PubMed ID: 19155306
[TBL] [Abstract][Full Text] [Related]
19. Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer.
Vafeiadou V; Hany D; Picard D
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205702
[TBL] [Abstract][Full Text] [Related]
20. Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells.
Pulliam N; Tang J; Wang W; Fang F; Sood R; O'Hagan HM; Miller KD; Clarke R; Nephew KP
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30621214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
